Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.64 |
| ▸ | CDK2 | P24941 | 6/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.46 |
| ▸ | CCND1 | P24385 | 3/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4109963 | 0.86 | ADORA2A (0.50) | ADORA2AADORA3CDK2CCNE1CCNE2 | |
| SCHEMBL239273 | 0.83 | ADORA2A (0.65) | ADORA2AADORA3ADORA1 | |
| Trifluoroacetic Acid SCHEMBL1402058 | 0.82 | ADORA2A (0.50) | ADORA2AADORA3CDK2CCNE1CCNE2 | |
| Trifluoroacetic Acid SCHEMBL1402000 | 0.82 | ADORA2A (0.66) | ADORA2AADORA3CDK2CCNE1CCNE2 | |
| Hydrochloric Acid SCHEMBL2883276 | 0.81 | ADORA2A (0.57) | ADORA2AADORA3CDK2CCNE1CCNE2 | |
| SCHEMBL590460 | 0.80 | ADORA2A (0.55) | ADORA2AADORA3CDK2CCNE1CCNE2 | |
| SCHEMBL1402070 | 0.80 | ADORA2A (0.71) | ADORA2AADORA3ADORA1 | |
| Trifluoroacetic Acid SCHEMBL4110783 | 0.79 | ADORA2A (0.63) | ADORA2AADORA3CDK2CCNE1CCNE2 | |
| SCHEMBL10156293 | 0.79 | ADORA2A (0.58) | ADORA2AADORA3ADORA1 | |
| SCHEMBL10155748 | 0.79 | ADORA2A (0.58) | ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805181-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| EP-2292619-A1 | Purine derivatives for use as adenonsin A-2A receptor agonists | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885CDK2 1405/4885 |
| US-20090105476-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885CDK2 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.